Author:
Kerklaan B Milojkovic,Lolkema M P J,Devriese L A,Voest E E,Nol-Boekel A,Mergui-Roelvink M,Langenberg M,Mykulowycz K,Stoebenau J,Lane S,Legenne P,Wissel P,Smith D A,Giantonio B J,Schellens J H M,Witteveen P O
Publisher
Springer Science and Business Media LLC
Reference43 articles.
1. Altorki N, Lane ME, Bauer T, Lee PC, Guarino MJ, Pass H, Felip E, Peylan-Ramu N, Gurpide A, Grannis FW, Mitchell JD, Tachdjian S, Swann RS, Huff A, Roychowdhury DF, Reeves A, Ottesen LH, Yankelevitz DF (2010) Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. J Clin Oncol 28: 3131–3137.
2. Anon (2013a) Hycamptin SmPC/Topotecan. Summary of product characteristics. Available at
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000123/WC500051542.pdf
.
3. Anon (2013b) Pazopanib SmPC/Votrient 200 mg and 400 mg film coated tablets Summary of Product Characteristics. The electronic Medicines Compendium (eMC). Available at
http://www.medicines.org.uk/emc/medicine/23148/spc
.
4. Bodnar L, Wcislo G, Nasilowska A, Szarlej-Wcislo K, Gasowska-Bodnar A, Smoter M, Szczylik C (2009) Salvage therapy with topotecan in heavily pretreated ovarian cancer patients. J Cancer Res Clin Oncol 135: 815–821.
5. Boers-Doets CB, Epstein JB, Raber-Durlacher JE, Ouwerkerk J, Logan RM, Brakenhoff JA, Lacouture ME, Gelderblom H (2012) Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. Oncologist 17: 135–144.
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献